A. Amro, Kanaan Mansoor, M. Amro, A. Sobeih, Obadah Aqtash, H. Hirzallah, Alaa Gabi, M. Urella, W. Ahmed, Sandra Shenouda, R. Sayyed
{"title":"普拉格雷在经皮冠状动脉介入治疗(PCI)后患者中的不当使用。单中心研究","authors":"A. Amro, Kanaan Mansoor, M. Amro, A. Sobeih, Obadah Aqtash, H. Hirzallah, Alaa Gabi, M. Urella, W. Ahmed, Sandra Shenouda, R. Sayyed","doi":"10.33470/2379-9536.1220","DOIUrl":null,"url":null,"abstract":"Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with acute coronary syndrome who undergo percutaneous coronary intervention. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.","PeriodicalId":93035,"journal":{"name":"Marshall journal of medicine","volume":"42 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study\",\"authors\":\"A. Amro, Kanaan Mansoor, M. Amro, A. Sobeih, Obadah Aqtash, H. Hirzallah, Alaa Gabi, M. Urella, W. Ahmed, Sandra Shenouda, R. Sayyed\",\"doi\":\"10.33470/2379-9536.1220\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with acute coronary syndrome who undergo percutaneous coronary intervention. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.\",\"PeriodicalId\":93035,\"journal\":{\"name\":\"Marshall journal of medicine\",\"volume\":\"42 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Marshall journal of medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33470/2379-9536.1220\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Marshall journal of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33470/2379-9536.1220","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study
Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with acute coronary syndrome who undergo percutaneous coronary intervention. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
